A Phase I Trial of Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Metastatic, Castrate-Resistant Prostate Cancer

Trial Profile

A Phase I Trial of Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Metastatic, Castrate-Resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs ATL 101 Telix Pharmaceuticals (Primary) ; Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Feb 2017 Planned End Date changed from 1 May 2016 to 1 May 2018.
    • 04 May 2015 Planned End Date changed from 1 May 2012 to 1 May 2016 as reported by ClinicalTrials.gov record.
    • 04 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top